Cidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results -- Single Ascending Dose Study-Results Demonstrate Excellent Safety and Tolerability and Support Once-Weekly IV Dosing -- -- Management to Host Webcast and Conference Call Tomorrow at 8:00 a.m. ET...